'김갑성' 기자의 전체기사
-
Strider Technologies Announces Partnership with NATO's D…
[ 메디채널 김갑성 기자 ] NATO DIANA will leverage Strider's strategic intelligence as economic security tool LONDON, Sept. 10, 2025 -- Strider Technologies, Inc. the leading provider of strategic intelligence, today announced its new partnership with NATO's Defence Innovation Accelerator for the North Atlantic (DIANA). Under this partnership, Strider will deliver its economic security capabilities to aid NATO DIANA in identifying contractual and supply chain risks from strategic competitors as set out in the NATO 2022 Strategic Concept. Strider's strategic intelligence will also be us
- 김갑성 기자
- 2025-09-10 16:00
-
UltiMaker、SシリーズのSecure Lineを発表、高セキュリティ・オンデマンド生産…
Secure Lineは、あらゆる環境において積層造形を最前線の戦術的能力へと変革します。 ニューヨークおよびゲルデルマルセン（オランダ）, 2025年9月10日 -- 防衛、製造、教育分野における3Dプリンティングの世界的リーダーであるUltiMakerは本日、防衛および高セキュリティ環境向けに設計された新たなSecure Line 3Dプリンティング製品の発売を発表しました。発売当初の主力製品は、UltiMaker S6 SecureとUltiMaker S8 Secureの2機種です。これらは陸上、海上、航空作戦において信頼性の高いオンデマンド生産能力を提供するために設計された堅牢なソリューションです。 安全で耐障害性があり、分散型の製造に対する需要が高まる中、Secure Lineは積層造形を配備可能な戦術資産へと転換する上で大きな前進を意味します。UltiMakerの実績あるプラットフォームを基盤とするS6 SecureおよびS8 Secureは、産業レベルの性能と、現代の防衛IT基準を満たすために設計された強化されたセキュリティ機能を兼ね備えています。 「Secure Lineは、積層造形技術を防衛組織にとって信頼性が高く配備可能な資産とする戦略的飛躍を体現しています」と、UltiMakerのE
- 김갑성 기자
- 2025-09-10 14:39
-
New Public Perception Survey Highlights Fragmented Cancer…
YouGov survey finds strong belief in value of early detection (76%) but low screening uptake (13%) Confidence in coordinated care (34%) and in 'one-stop' care (36%) among the lowest in Southeast Asia Strongest regional demand for advanced technology in follow-up care and recurrence detection (58%) MANILA, Philippines, Sept. 10, 2025 -- Public perceptions of cancer care in the Philippines show critical gaps across the pathway from screening and diagnosis through to treatment and survivorship, according to new research commissioned by Siemens Healthineers. &nb
- 김갑성 기자
- 2025-09-10 14:00
-
Taiwanese Women's Shifting Views on Childbirth: Autonomy…
TAIPEI, Sept. 10, 2025 -- The attitude of Taiwanese women toward childbirth is rapidly changing. With the legalization of same-sex marriage, rising educational attainment among female, and increased participation in the workforce, the traditional model of "marriage necessarily leading to childbirth" is no longer the norm. According to data from the Ministry of the Interior, the average age of first-time mother in Taiwan has exceeded 33, and the total fertility rate has fallen to the lowest in the world. Many women are choosing to delay childbirth, have fewer children, or forgo havin
- 김갑성 기자
- 2025-09-10 13:53
-
Leaft Foods、Lacto Japanと提携し、革新的なリーフ・ルビスコ・プロテイ…
[ 메디채널 김갑성 기자 ] 戦略的パートナーシップにより、Lacto の市場専門知識を活用し、日本のイノベーション主導型食品メーカーに次世代プロテインを提供 ニュージーランド・ロールストンおよび東京、2025年9月10日 -- Leaft Foods緑葉から直接抽出した地球上で最も豊富なタンパク質を活用し、業界をリードする製品を生み出している企業が、本日、特殊食品原料の主要なディストリビューター兼生産者である企業との[ 메디채널 김갑성 기자 ] 戦略的パートナーシップLacto Japan Co., Ltd.を発表しました。この協業により、Leaft の画期的なルビスコ・プロテイン・アイソレートの商業化が、日本の高度な食品製造業界において加速されることとなります。 Leaft のRubisco Protein Isolateは、タンパク質業界におけるパラダイムシフトを示しています。Rubisco の特筆すべき点は、栄養面と機能面の特性を兼ね備え、ホエイプロテインなどの動物由来タンパク質を凌駕していることです。Leaf Rubiscoは、ホエイプロテインを上回るアミノ酸プロファイルを提供し、タンパク質栄養における新たなゴールドスタンダードを確立します。 卓越した栄養プロファイルに加え、Leaf Rubiscoは優れた食品機能
- 김갑성 기자
- 2025-09-10 13:20
-
New Public Perception Survey Highlights Fragmented Cancer…
YouGov survey finds strong belief in value of early detection (88%) but under half screened (40%) 84% of respondents aware post-treatment care exists, 55% lack understanding of what it involves Findings show confidence in "one-stop" cancer services and cautious optimism for digital innovation BANGKOK , Sept. 10, 2025 -- Public perceptions of cancer care in Thailand show critical gaps across the pathway from screening and diagnosis through to treatment and survivorship, according to new research commissioned by Siemens Healthineers. Bridgi
- 김갑성 기자
- 2025-09-10 11:39
-
New Public Perception Survey Highlights Fragmented Cancer…
YouGov survey finds belief in value of early detection (65%) but very low screening uptake (8%) 76% of respondents aware post-treatment care exists, 58% lack understanding of what it involves Confidence in coordinated care (39%) and in 'one-stop' care (31%) among lowest in Southeast Asia JAKARTA, Indonesia, Sept. 10, 2025 -- Public perceptions of cancer care in Indonesia show critical gaps across the pathway from screening and diagnosis through to treatment and survivorship, according to new research commissioned by Siemens Healthineers. Bridging t
- 김갑성 기자
- 2025-09-10 11:24
-
Korea Health Functional Food Association to Showcase Glo…
[ 메디채널 김갑성 기자 ] Operating a Korea Health Functional Food Promotional Booth under the 'K-Health W.A.V.E' slogan Introduces Korea's system, research achievements, and new technologies through seminars featuring the Ministry of Food and Drug Safety and member companies SEOUL, South Korea, Sept. 10, 2025 -- The Korea Health Functional Food Association (KHFF) will participate in "Vitafoods Asia 2025," to be held from September 17 to 19 at the Queen Sirikit National Convention Center (QSNCC) in Bangkok, Thailand, and will showcase the excellence and technological capabilities
- 김갑성 기자
- 2025-09-10 11:00
-
ImmVira Announces First-in-Human Data of Engineered Exoso…
SUZHOU, China, Sept. 10, 2025 -- ImmVira Group ("ImmVira" or the "Company") recently announced that its lead engineered exosome candidate, MVR-EX105 ("EX105") is featured in a poster presentation at the 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Founded in 1995, IFSO is a leading international professional organization comprising bariatric and metabolic surgeons and integrated health professionals worldwide. It is dedicated to providing optimal surgical care for obesity, improving the tre
- 김갑성 기자
- 2025-09-10 10:49
-
Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combinati…
HONG KONG, Sept. 10, 2025 -- Akeso Inc. (9926.HK) announced that data from a Phase Ib/II clinical study evaluating the combination of cadonilimab and pulocimab (an anti-VEGFR-2 antibody) in patients with immunotherapy (IO)-resistant NSCLC were presented in a Mini Oral session at the 2025 World Conference on Lung Cancer (WCLC). This marks the first clinical data release for cadonilimab in IO-resistant lung cancer. The cadonilimab combination therapy for advanced squamous non-small cell lung cancer (NSCLC) progressing after PD-(L)1 inhibitor treatment, has previously received Breakthrough Thera
- 김갑성 기자
- 2025-09-10 10:40
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-22_WED
2025-10-21_TUE
- AESOP Technology announces DxPrime is now a qualified solution on Mayo Clinic Platform 23:30
- Charming Medical Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq 23:00
- Stéphane Rolland's Haute Couture to Illuminate the 10th Anniversary of Barcelona Bridal Night 23:00
- JOY GROUP Completes Acquisition of Italian Dermatological Hair Care Brand Foltène 22:00
- AI meets capital: Bizcap welcomes 8fig into its global portfolio to accelerate growth funding 22:00
- Youth Innovation Safeguards Green Heritage: 2025 World Food Forum Youth Action on Green Agri-Heritage Held in Rome 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 22일 03시 00분